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We wish to highlight that based on a single abnormal psy-
chometry test (NCT-A), they labeled 95% of their patients as hav-
ing minimal hepatic encephalopathy (MHE); however, according
to Ferenci et al. [2] two or more abnormal psychometric tests are
needed to label patients with MHE which is a better terminology
than SHE. Although it is not clear to us which sedation (propofol/
midazolam) was given to them, they took 30 controls with no
liver disease and found no deterioration/improvement in NCT-A
tests; looking at the induction and recovery time it seems that
they were given propofol. The primary result of the study that
midazolam prolongs the psychometry tests in cirrhotics would
be better appreciated if the effect of midazolam on psychometric
tests was assessed in the control arm. The second end point of the
study was that patients can be discharged early if an endoscopy
was done under propofol. At what time patients can be dis-
charged after endoscopy is a big question that has not been well
addressed. The mean time of recovery was higher in the midazo-
lam group compared to propofol (11.5 ± 5.0 vs 4.1 ± 1.9 min,
p <0.001); the parameters taken to discharge the patients at
110.0 ± 42.0 min in the midazolam group and 38.0 ± 9.0 min in
the propofol group was not clear. Some objective parameters
before discharge like Post-Anesthetic Discharge Scoring System
or the Aldrete scoring system should be used. The authors of this
study planned to repeat a NCT-A after 1 h in sedated patients;
however, this statement is contradicted by the fact that the mean
time to discharge in the propofol group was 38.0 ± 9.0 min. We
are also confused about what happened to the patients in the
midazolam group who had an increased NCT-A after endoscopy.
It would be important to know whether during follow up of
24–48 h in these patients there was any side effects related to
sedation in either group.
Previous studies have shown that a learning effect is associ-
ated with psychometry tests [3,4]. Consequently, a deterioration
in the performance of patients in these tests would be difﬁcult
to pick up by repeating these tests. Tests like critical ﬂicker fre-
quency or inhibitory control test would be better adapted for this
assessment. In addition, they observed transient hypoxemia
(<90% saturation) in four patients (two in each group) but none
in controls, implying that cirrhotic patients are more prone to
transient hypoxemia after sedation. From the study, it was not
clear whether patients under sedation received prophylactic oxy-
gen; moreover, the patients’ American Society of Anesthesiolo-
gists Physical Status (ASA) score was also not provided, as it
might affect the outcome of psychometry tests and recovery time.
In our experience (unpublished data) of more than 1000
endoscopies (both in cirrhotics and non-cirrhotics) performed
over a year under propofol sedation (Modiﬁed Observer’s Assess-
ment of Alertness/Sedation Scale score 1), we agree with the
results by Khamaysi et al. that propofol sedation is safe in per-
forming upper gastrointestinal endoscopy in cirrhotic patients
when given by anesthetist. In fact, all of our patients could be dis-
charged at 2 h post-endoscopy. However, two or more psychom-
etry tests/CFF/ICT need to be performed to evaluate cognitive
function before and after endoscopy, as well as a longer follow
up to ensure that propofol does not exacerbate MHE.
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Letters to the EditorSub-clinical hepatic encephalopathy in cirrhotic patients is
not aggravated by sedation with propofol compared
to midazolam: A randomized controlled studyThis is a reply to the Letter to the Editor by Sharma et al.
Thank you very much for the interesting comments by Dr.
Sharma et al. We agree that hepatic encephalopathy is better
deﬁned by multiple psychometric tests than a single psychomet-
ric test, but NCT-A can still reliably detect minimal degrees of
hepatic encephalopathy. Moreover, NCT is considered the stan-1322 Journal of Hepatology 201dard in this area because of its sensitivity, ease of application,
and quantitative aspect [1].We agree that minimal hepatic
encephalopathy (MHE) may be a more precise terminology than
sub-clinical hepatic encephalopathy (SHE).
In our study, patients in the control group were given midaz-
olam sedation and were discharged from the endoscopy unit as1 vol. 54 j 1320–1326
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mentioned in the study, but they were kept in the department for
further observation and evaluation. Unfortunately, the objective
parameters before discharge such as Post-Anesthetic Discharge
Scoring System or Aldrete scoring systemwere not used. The long
term follow up and side effects related to sedation were not done
in our study.
Regarding the hypoxemia events, all the subjects received
supplementary oxygen by nasal prongs. The hypoxemia events,
which were slight and transient, were noticed only in the cir-
rhotic group. The statement that this group might be more prone
to develop desaturation could be true, albeit, with no statistical
signiﬁcance. The American Society of Anesthesiologists Physical
Status (ASA) score was not calculated, although, this parameter
may inﬂuence the recovery time [2].
In conclusion, we agree that it is better and safer to apply a
multiple psychometric tests before discharging, but this can off-
set the advantage of the reduced recovery time in patients
sedated with propofol. Longer follow up period can easily be
taken even by a phone call 1–2 days after the procedure. Accord-
ing to this approach, MHE can be diagnosed and treated rapidly.
Finally, a discharge from the hospital at 2 h post endoscopy
seems to be very safe [3].Acute autochthonous hepatitis
underlying chronic liver dis
To the Editor:
We read with interest the recent editorial in the Journal of Hepa-
tology entitled ‘‘Hepatitis E: Water, water everywhere – Now a
Global Disease’’ [1]. The authors state that in industrialized
nations, acute liver failure and acute-on-chronic liver failure
due to autochthonous acute hepatitis E genotype 3 (HEV3) infec-
tion have not yet been documented. This statement is inaccurate.
A series of seven patients with fulminant liver failure from acute
autochthonous HEV3 infection have been reported from south-
west France [2]. Six of these patients had chronic liver disease
and ﬁve were active drinkers. Five of these patients died. In
addition, acute HEV3 infection was reported as a cause of decom-
pensation in three patients with chronic liver disease in the UK
[3]. Two of these patients died from sub-acute liver failure.
In the past three years (January 2008–December 2010) 35
more cases of acute hepatitis E in immunocompetent patients
were diagnosed in the Toulouse University Hospital. Of these,
nine patients (26%) had underlying chronic liver disease, of which
seven were alcoholic. There were seven males and the median
age was 47 years (36–79). All cases were autochthonous. Four
patients (44%) had ascites and two had encephalopathy. Median
serum bilirubin was 127 lmol/L (29.6–704.4). The strains were
sequenced in four patients. They were all genotype 3; subtype
3f in three patients, subtype 3c in one. Three patients died (33%).
The two most recent patients were treated with ribavirin
monotherapy. A 79 year old patient with chronic liver disease
was admitted for acute hepatitis and acute kidney failure requir-
ing renal replacement therapy. HEV RNA was found to be positive
both in the serum and the stools and all other causes of hepatitis
were ruled out, including acute alcoholic hepatitis. Because of the
severe presentation, the advanced age of the patient, and since
we had shown earlier this year that ribavirin is effective and well
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tolerated in the treatment of chronic hepatitis E in kidney-trans-
plant patients [4], he was given ribavirin monotherapy in order to
rapidly contain viral replication. Ribavirin was started off at a
dose of 200 mg every other day because of the acute kidney fail-
ure. The treatment was scheduled for a 3 month period. Serum
HEV RNA concentration decreased from 6.36 log copies/ml at the
initiation of the therapy to 4.6 log copies/ml at day 10, 2.9 log
copies/ml at day 17, and was negative at one month. The patient
completely recovered and dialysis was stopped at month two.
The second patient was treated for 10 days at a dose of
1000 mg per day in two divided doses. Viral load was 4.07 log-
copies/ml before treatment, 3.08 after 3 days, 2.54 after 6 days
and undetectable one month later. Hemoglobin levels dropped
from 12.6 g/dl before treatment to 11.6 g/dl after 6 days of treat-
ment. There were no other ribavirin induced side effects. There
was no viral relapse in these two patients.
These data show that the prognosis of acute autochthonous
hepatitis E can be poor in industrialized nations, particularly in
patients with chronic liver disease (acute on chronic liver failure),
and is similar to that reported for HEV genotype 1 infection in
patients with chronic liver disease in the Indian sub-continent
[5]. An Anglo-Frenchmulticentre study is ongoing to assess its fre-
quency and its induced-mortality in a larger number of patients.
Short term ribavirin treatment may be useful in these patients.
However, this hypothesis needs to be further investigated.
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